Publication Topic

Thompson CM, Aardema MJ, Heintz MM, MacGregor JT, Young RR. 2021. A review of mammalian in vivo genotoxicity of hexavalent chromium: implications for oral carcinogenicity risk assessment. Crit Rev Toxicol 51(2), https://doi.org/10.1080/10408444.2021.2000934.

Bhat VS, Cohen SM, Gordon EB, Wood CE, Cullen JM, Harris MA, Proctor DM, Thompson CM. 2020. An adverse outcome pathway for small intestinal tumors in mice involving chronic cytotoxicity and regenerative hyperplasia: A case study with hexavalent chromium, captan, and folpet. Crit Rev Toxicol 50(8)685-706; doi: 10.1080/10408444.2020.1823934.

Rager JE, Suh M, Chappell G, Thompson CM, Proctor DM. 2019. Review of transcriptomic responses to hexavalent chromium exposure in lung cells supports a role of epigenetic mediators in carcinogenesis. Toxicol Lett 305:40-50.

Moffat I, Martinova N, Seidel C, Thompson CM. 2018. Hexavalent chromium in drinking water. Journal AWWA 110:5.

Thompson CM, Kirman CR, Hays SM, Suh M, Harvey SE, Proctor DM, Rager JE, Haws LC, Harris MA. 2018. Integration of mechanistic and pharmacokinetic information to derive oral reference dose and margin-of-exposure values for hexavalent chromium. J Appl Toxicol 38:351–365. doi: 10.1002/jat.3545.

Thompson CM, Young RR, Dinesdurage H, Suh M, Harris MA, Rohr AC, Proctor DM. 2017. Assessment of the mutagenic potential of hexavalent chromium in the duodenum of Big Blue® rats. Toxicol Appl Pharmacol 330(1):48-52; 10.1016/j.taap.2017.07.002.

Rager JE, Ring CL, Fry RC, Suh M, Proctor DM, Haws L, Harris MA, Thompson CM. 2017. High-throughput screening data interpretation in the context of in vivo transcriptomic responses to oral Cr(VI) exposure. Toxicol Sci 158(1):199–212; doi: 10.1093/toxsci/kfx085.

Kirman CR, Suh M, Proctor DM, Hays SM. 2017. Improved physiologically based pharmacokinetic model for oral exposures to chromium in mice, rats, and humans to address temporal variation and sensitive populations. Toxicol Appl Pharmacol 325:9-17.

Thompson C, Rager J, Suh M, Proctor D, Haws L, Harris M. Mechanistic support for nonlinear risk assessment of rat oral cavity tumors induced by exposure to Cr(VI) in drinking water. Poster presented at 56th Society of Toxicology Annual Meeting. March 15, Baltimore, MD, March 2017.

Thompson CM, Bichteler A, Rager JE, Suh M, Proctor DM, Haws LC, Harris MA. 2016. Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium. Mut Res/Genet Toxicol Environ Mutagen 800-801:28-34; doi: 10.1016/j.mrgentox.2016.01.008.

Thompson CM, Rager JE, Suh M, Ring CL, Proctor DM, Haws LC, Fry RC, Harris MA. 2016. Transcriptomic responses in the oral cavity of F344 rats and B6C3F1 mice following exposure to Cr(VI): Implications for risk assessment. Environ Molec Mutagen 57:706-716.

De Flora S, Camoirano A, Micale RT, La Maestra S, Savarino V, Zentilin P, Marabotto E, Suh M, Proctor DM. 2016. Reduction of hexavalent chromium by fasted and fed human gastric fluid.  I. Chemical reduction and mitigation of mutagenicity. Toxicol Appl Pharmacol   306:113-119.

Kirman CR, Suh M, Hays SM, Gürleyük H, Gerads R, De Flora S, Parker W, Lin S, Haws LC, Harris MA, Proctor DM. 2016. Reduction of hexavalent chromium by fasted and fed human gastric fluid.  II. Ex vivo gastric reduction modeling. Toxicol Appl Pharmacol 306:120-133.

Thompson CM. Non-mutagenic MOA for Cr(VI) involving intestinal cytotoxicity and regenerative hyperplasia. Platform presentation in the “The Cancer Risk Assessment for Ingested Hexavalent Chromium: Challenges and Controversies” Session. Presented at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

Thompson CM, Suh M, Proctor DM, Rager JE, Haws LC, Harris MA. Assessment of the in vivo genotoxicity of CrVI in target organs identified in a two-year cancer bioassay. Presented at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

Cullen JM, Ward JM, Thompson CM. 2016. Reevaluation and classification of duodenal lesions in B6C3F1 mice and F344 rats from 4 studies of hexavalent chromium in drinking water. Toxicologic Pathol 44(2):279-89.

Proctor DM, Suh M, Mittal L, Hirsch S, Salgado RV, Bartlett C, Van Landingham C, Rohr A, Crump K. 2015. Inhalation cancer risk assessment of hexavalent chromium based on updated mortality for Painesville chromate production workers. J Expo Sci Environ Epidemiol 26(2):224-231. doi: 10.1038/jes.2015.77.

Thompson CM, Wolf JC, Elbekai RH, Paranjpe MG, Seiter JM, Chappell MA, Tappero RV, Suh M, Proctor DM, Bichteler A, Haws LC, Harris MA. 2015. Duodenal crypt health following exposure to Cr(VI): Micronucleus scoring, γ-H2AX immunostaining, and synchrotron x-ray fluorescence microscopy. Mut Res 789–790:61–66.

Thompson CM, Young RR, Suh M, Dinesdurage HR, Elbekai RH, Harris MA, Rohr AC, Proctor DM. 2015. Assessment of the mutagenic potential of Cr(VI) in the oral mucosa of Big Blue® transgenic F344 rats. Environ Mol Mutagen 56(7):621-628; doi: 10.1002/em.21952.

Young RR, Thompson CM, Dinesdurage HR, Elbekai RH, Suh M, Rohr AC, Proctor DM. 2015. A robust method for assessing chemically induced mutagenic effects in the oral cavity of transgenic Big Blue® rats. Environ Mol Mutagen 56:629-636.